Connecting you with your industry every day
The hardline UK industry watchdog is at it again, slapping a company with 11 breaches of the Code over a single webpage on a Congress website after a complaint from an ex-employee which described the company's missteps as an embarrassment to the industry
The MFN isn't going anywhere soon, and the Commonwealth will need to adjust its pricing expectations if it wants Australians to gain access to the latest medicines
An update to the TGA's prescription medicines under evaluation list shows 11 drug applications were accepted in August, signalling what could enter the Australian market next year
Potential first-in-class treatment for a disease with high unmet need falls at the finish line of a pivotal trial after this pharma paid a hefty price in July
While RRMS is a PBS success story with Australians having the best access to meds in the world, there are new drugs coming that also need to be funded
The number of blockbuster drugs have skyrocketed, with a new report taking a deep dive into whether industry can sustain the boom in the face of looming patent cliffs
The first oral GLP-1 drug has been approved for use in Australia for weight loss and will likely hit the private market this year, with a rival hot on its heels
Just months after undergoing a major rebrand, this Australian biotech is embarking on its next phase of growth, with plans to establish a US subsidiary
The decision came despite a high-priority recommendation from its Advisory Group with the current fiscal environment and constraints of the public health system to blame
The UK pharma giant has announced a "reshaping" programme which will see jobs lost in some areas but gained in others
In the latest round of job moves, industry leaders move up alongside long-timers changing companies - one after almost 30 years working at the same pharma
A drug currently seeking to unlock broader government subsidy in Australia was crowned one of the best products of 2026 at the Prix Galien USA awards
South Australian researchers have described one of Novartis' fastest-growing brands as "a huge step forward" in frontline treatment options
AdvanCell has challenged two patent application by a Norwegian company that cover the production of the radioisotope used in its flagship product
So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth
TGA wins its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"
After this drug wowed ESMO last month Australian researchers have discovered another combo that could disrupt treatment for small cell lung cancer
Eight drugs won reimbursement over the weekend, with half of the medicines belonging to one pharma
As concerns grow over Australia’s lagging access to medicines, AbbVie has released a report exposing just how far the country has fallen behind and who is paying the price
The TGA has approved the first copycats of long-standing drugs sponsored by Bayer, Link Medical Products, and Novo in Australia
Melbourne-based pharma notches another win in the US with the granting of an Orphan Drug designation, marking an important commercial milestone
Company rockets past analyst predictions thanks to a booming private market for its weight loss medications, smashing forecasts for the third quarter running
The prices of new drugs at launch rose by over a third from 2022 to 2025, but the trend came to an abrupt end in the last year. Is this the start of a new era?
New poll puts pressure on Govt to freeze the PBS co-pay at $25 amid a cost-of-living crisis, just a couple of months out from a scheduled price hike
AbbVie helps inspire the next generation of changemakers by backing the Future Health Leaders Program alongside Research Australia and the CSIRO
One company shot up the rankings by four places to be declared the top Big Pharma when it comes to corporate reputation, judged by diabetes patients
Acting PBAC Chair tells Senate Estimates that "sponsors are just not commercially enticed" to paediatric populations
J&J has started proceedings to prevent four companies from launching generic versions of one of its drugs, but a fifth decided it also wanted to get involved
A new member of Medicines Australia has seen the ranks of the industry organisation swell to 50